Aviva’s AbbVie ABBV Stock Holding History

Aviva’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$333M	Buy	1,531,018 +44,957	+3%	+$9.97M	0.56%	27
2025 Q4	$340M	Buy	1,486,061 +79,495	+6%	+$18.1M	0.57%	24
2025 Q3	$326M	Buy	1,406,566 +84,051	+6%	+$17.1M	0.59%	24
2025 Q2	$245M	Buy	1,322,515 +98,463	+8%	+$18.3M	0.51%	28
2025 Q1	$256M	Buy	1,224,052 +270,163	+28%	+$52.5M	0.62%	27
2024 Q4	$170M	Buy	953,889 +18,294	+2%	+$3.36M	0.44%	36
2024 Q3	$185M	Buy	935,595 +19,173	+2%	+$3.58M	0.48%	34
2024 Q2	$157M	Buy	916,422 +146,614	+19%	+$24.3M	0.44%	35
2024 Q1	$140M	Buy	769,808 +30,616	+4%	+$5.28M	0.46%	35
2023 Q4	$115M	Buy	739,192 +4,383	+0.6%	+$639K	0.41%	42
2023 Q3	$110M	Buy	734,809 +28,958	+4%	+$4.25M	0.46%	35
2023 Q2	$95.1M	Buy	705,851 +123,802	+21%	+$18.2M	0.39%	42
2023 Q1	$92.8M	Sell	582,049 -63,304	-10%	-$9.68M	0.42%	29
2022 Q4	$104M	Buy	645,353 +96,966	+18%	+$14.9M	0.51%	29
2022 Q3	$73.6M	Sell	548,387 -33,551	-6%	-$4.81M	0.42%	35
2022 Q2	$89.1M	Buy	581,938 +104,770	+22%	+$16M	0.47%	28
2022 Q1	$77.4M	Sell	477,168 -79,237	-14%	-$11.5M	0.39%	42
2021 Q4	$75.3M	Sell	556,405 -88,324	-14%	-$10.4M	0.32%	63
2021 Q3	$69.5M	Sell	644,729 -10,455	-2%	-$1.19M	0.31%	68
2021 Q2	$73.8M	Buy	655,184 +26,554	+4%	+$2.99M	0.32%	69
2021 Q1	$68M	Sell	628,630 -195,805	-24%	-$20.9M	0.33%	69
2020 Q4	$88.3M	Sell	824,435 -22,369	-3%	-$2.15M	0.46%	47
2020 Q3	$74.2M	Sell	846,804 -26,712	-3%	-$2.51M	0.44%	52
2020 Q2	$85.8M	Buy	873,516 +317,148	+57%	+$27.9M	0.53%	41
2020 Q1	$42.4M	Buy	556,368 +27,945	+5%	+$2.38M	0.31%	72
2019 Q4	$46.8M	Sell	528,423 -40,111	-7%	-$3.33M	0.28%	79
2019 Q3	$43M	Sell	568,534 -41,780	-7%	-$2.86M	0.29%	82
2019 Q2	$44.4M	Sell	610,314 -25,172	-4%	-$1.98M	0.3%	75
2019 Q1	$51.2M	Buy	635,486 +1,587	+0.3%	+$130K	0.34%	70
2018 Q4	$58.4M	Sell	633,899 -181,800	-22%	-$16M	0.44%	60
2018 Q3	$77.1M	Sell	815,699 -73,165	-8%	-$6.94M	0.42%	61
2018 Q2	$82.4M	Sell	888,864 -11,353	-1%	-$1.11M	0.49%	43
2018 Q1	$85.2M	Sell	900,217 -76,376	-8%	-$8.39M	0.52%	44
2017 Q4	$94.4M	Sell	976,593 -173,667	-15%	-$16.4M	0.53%	43
2017 Q3	$102M	Buy	1,150,260 +11,909	+1%	+$907K	0.55%	41
2017 Q2	$82.5M	Buy	1,138,351 +2,660	+0.2%	+$179K	0.46%	47
2017 Q1	$74M	Sell	1,135,691 -61,873	-5%	-$3.89M	0.42%	50
2016 Q4	$75M	Sell	1,197,564 -65,999	-5%	-$4.03M	0.45%	45
2016 Q3	$79.7M	Buy	1,263,563 +133,225	+12%	+$8.62M	0.5%	45
2016 Q2	$70M	Sell	1,130,338 -222,555	-16%	-$13.6M	0.48%	48
2016 Q1	$77.3M	Sell	1,352,893 -25,936	-2%	-$1.45M	0.57%	39
2015 Q4	$81.7M	Buy	1,378,829 +339,159	+33%	+$19.5M	0.62%	37
2015 Q3	$56.6M	Sell	1,039,670 -46,741	-4%	-$3.04M	0.47%	48
2015 Q2	$73M	Sell	1,086,411 -13,095	-1%	-$855K	0.52%	44
2015 Q1	$64.4M	Buy	1,099,506 +225,224	+26%	+$13.6M	0.44%	53
2014 Q4	$57.2M	Buy	874,282 +20,484	+2%	+$1.29M	0.44%	55
2014 Q3	$49.3M	Sell	853,798 -1,041	-0.1%	-$57.8K	0.39%	56
2014 Q2	$48.2M	Buy	854,839 +25,342	+3%	+$1.33M	0.37%	56
2014 Q1	$42.6M	Buy	829,497 +107,664	+15%	+$5.44M	0.35%	65
2013 Q4	$38.1M	Sell	721,833 -11,508	-2%	-$566K	0.32%	74
2013 Q3	$32.8M	Buy	733,341 +83,702	+13%	+$3.71M	0.29%	83
2013 Q2	$26.9M	Buy	+649,639	New	+$28.4M	0.27%	94

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Aviva's ABBV Position: Q1 2026 in Review

Aviva increased its AbbVie (ABBV) stake by 3% in Q1 2026, buying an estimated $9.97M and bringing the position to 1,531,018 shares worth $333M. The position accounts for 0.56% of the portfolio, ranked #27.

Aviva first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $340M in Q4 2025. 4,079 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Aviva held 1,531,018 shares of AbbVie worth $333M as of Q1 2026.
Aviva bought 44,957 AbbVie shares in Q1 2026, an estimated $9.97M.
AbbVie made up 0.56% of Aviva's portfolio in Q1 2026, its #27 holding.
Aviva first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
Aviva's AbbVie position peaked at $340M in Q4 2025.
4,079 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Aviva's 13F filing for Q1 2026, filed 14 May 2026.